• Sofinnova Partners closed its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million), surpassing its initial target.
• The firm is a leading European life sciences VC based in Paris, London, and Milan.
• Sofinnova Capital XI will invest in pioneering biopharmaceutical and medical technology companies addressing urgent unmet clinical needs.
• The fund leverages Sofinnova’s multi-strategy platform and experienced partners: Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.
• Strong support came from global blue-chip institutional investors, including sovereign wealth funds, major pharmaceutical companies, corporates, insurance firms, foundations, and family offices.
• Commitments were secured from Europe, North America, Asia, and the Middle East, with a majority of returning LPs plus new top-tier investors.
• The fundraising success reflects confidence in Sofinnova’s disciplined strategy and long-standing track record.
• Antoine Papiernik emphasized that the fund allows Sofinnova to double down on early-stage opportunities and continue its science-driven, collaborative approach. He noted that reaching this milestone despite a volatile fundraising environment demonstrates continued investor confidence.
• Sofinnova Capital XI is already deploying capital and has invested in several portfolio companies.
• The fund will continue supporting early-stage biotech and medtech ventures in Europe and North America, participating in both initial and follow-on rounds.
